实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2014年
9期
5-8,14
,共5页
钱晓涛%赵腊梅%何圆%尤长宣
錢曉濤%趙臘梅%何圓%尤長宣
전효도%조석매%하원%우장선
非小细胞肺癌%吉非替尼%维持治疗
非小細胞肺癌%吉非替尼%維持治療
비소세포폐암%길비체니%유지치료
non-small-cell lung cancer%gefitinib%maintenance therapy
目的:评价晚期非小细胞肺癌(NSCLC)一线化疗后,疗效非进展患者给予吉非替尼维持治疗的疗效与安全性。方法将46例一线化疗后疗效非进展NSCLC患者按治疗方法不同分为2组:对照组18例采用最佳支持疗法(BSC)治疗,观察组28例在BSC治疗基础上给予吉非替尼维持治疗。比较2组的临床疗效与不良反应发生情况。结果观察组总有效率(RR)28.6%,疾病控制率(DCR)82.1%;对照组RR 5.6%, DCR 62.1%,2组比较差异均无统计学意义(P>0.05)。观察组无进展生存期(PFS)显著高于对照组(中位PFS 11.07个月比3.77个月,P=0.006);观察组总生存期(OS)30.07个月,对照组18.17个月,2组比较差异无统计学意义(P=0.24)。观察组常见不良反应有皮疹(15/28,53.6%)、转氨酶升高(7/28,25.0%)、腹泻(6/28,21.4%)。结论吉非替尼维持治疗晚期非小细胞肺癌安全有效,能延长患者生存期。
目的:評價晚期非小細胞肺癌(NSCLC)一線化療後,療效非進展患者給予吉非替尼維持治療的療效與安全性。方法將46例一線化療後療效非進展NSCLC患者按治療方法不同分為2組:對照組18例採用最佳支持療法(BSC)治療,觀察組28例在BSC治療基礎上給予吉非替尼維持治療。比較2組的臨床療效與不良反應髮生情況。結果觀察組總有效率(RR)28.6%,疾病控製率(DCR)82.1%;對照組RR 5.6%, DCR 62.1%,2組比較差異均無統計學意義(P>0.05)。觀察組無進展生存期(PFS)顯著高于對照組(中位PFS 11.07箇月比3.77箇月,P=0.006);觀察組總生存期(OS)30.07箇月,對照組18.17箇月,2組比較差異無統計學意義(P=0.24)。觀察組常見不良反應有皮疹(15/28,53.6%)、轉氨酶升高(7/28,25.0%)、腹瀉(6/28,21.4%)。結論吉非替尼維持治療晚期非小細胞肺癌安全有效,能延長患者生存期。
목적:평개만기비소세포폐암(NSCLC)일선화료후,료효비진전환자급여길비체니유지치료적료효여안전성。방법장46례일선화료후료효비진전NSCLC환자안치료방법불동분위2조:대조조18례채용최가지지요법(BSC)치료,관찰조28례재BSC치료기출상급여길비체니유지치료。비교2조적림상료효여불량반응발생정황。결과관찰조총유효솔(RR)28.6%,질병공제솔(DCR)82.1%;대조조RR 5.6%, DCR 62.1%,2조비교차이균무통계학의의(P>0.05)。관찰조무진전생존기(PFS)현저고우대조조(중위PFS 11.07개월비3.77개월,P=0.006);관찰조총생존기(OS)30.07개월,대조조18.17개월,2조비교차이무통계학의의(P=0.24)。관찰조상견불량반응유피진(15/28,53.6%)、전안매승고(7/28,25.0%)、복사(6/28,21.4%)。결론길비체니유지치료만기비소세포폐암안전유효,능연장환자생존기。
Objective To evaluate the efficacy and safety of gefitinib maintenance therapy in advanced non-small-cell lung cancer(NSCLC)patients without disease progression after first-line che-motherapy.Methods Forty-six NSCLC patients without disease progression after first-line chemo-therapy were given the best support therapy (control group, n=18) or in combination with gefitinib maintenance therapy (observation group, n=28). Clinical efficacy and adverse reactions were compared between the two groups. Results The overall response rate was 28.6% in observation group and 5.6%in control group. The disease control rate was 82.1% in observation group and 62.1% in control group. There were no significant differences in the overall response rate and disease control rate between the two groups (P>0.05).Compared with control group, the median progression-free survival was significantly prolonged in observation group (11.07 months vs 3.77 months, P=0.006). However, the difference in the overall survival was not significant between observation group and control group (30.07 months vs 18.17 months, P=0.24). In observation group, the common adverse events included rash (15/28, 53.6%) , ALT increased (7/28, 25.0%) and diarrhea (6/28, 21.4%). Conclusion Gefitinib maintenance therapy is effective and safe and can prolong survival in patients with NSCLC.